Capricor Therapeutics (CAPR) Projected to Announce Earnings on Monday

Capricor Therapeutics (NASDAQ:CAPR) is expected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.1278) per share and revenue of $41.71 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, analysts expect Capricor Therapeutics to post ($1.71) EPS for the current fiscal year and ($1.19) EPS for the next fiscal year.

Capricor Therapeutics Stock Up 7.2%

Capricor Therapeutics stock opened at $6.84 on Monday. The company has a market capitalization of $397.79 million, a P/E ratio of -2.78 and a beta of 0.61. The stock’s 50 day moving average is $8.06 and its 200 day moving average is $20.60. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37.

Analyst Upgrades and Downgrades

CAPR has been the topic of several recent research reports. B. Riley Financial raised Capricor Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $5.00 to $21.00 in a research note on Monday, September 14th. Alliance Global Partners cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research note on Tuesday, July 28th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Finally, JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.25.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.